UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT ~~PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

~~Date~~Pursuant ofto ~~report~~Section 13 or 15(~~Date~~d) of ~~earliest~~the ~~event reported):~~Securities ~~August~~Exchange 7,Act ~~2020~~of 1934

~~VITASPRING~~Date ~~BIOMEDICAL~~of ~~CO.~~Report ~~LTD.~~(Date of earliest event reported): January 17, 2023

VITASPRING BIOMEDICAL CO. LTD. (Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Charter~~its charter)

NV	333-216465	37-1836726
Nevada	333-216465	37-1836726
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
400 Spectrum Center Dr. 1620 Irvine, CA 92618
(Address of Principal Executive Offices) (Zip Code)

400 Spectrum Center Dr. suite 1620 Irvine, CA 92618 (~~949)2029235~~Address of Principal Executive Offices)

(~~Registrant's~~949) ~~telephone~~202-9235 ~~number, including area code)~~

(~~Former~~Registrant’s ~~name or former address~~telephone number, ifincluding ~~changed~~area ~~since last report~~code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~____________________________________________________________________________________~~Item 4.01 Changes in Registrant’s Certifying Accountant.

~~Item~~(a) ~~5.02~~Dismissal ~~Departure~~ of ~~Directors~~Independent orRegistered ~~Principal~~Public ~~Officers;~~Accounting ~~Election of Directors; Appointment of Principal Officers.~~Firm

~~Effective~~On ~~August~~January 717, ~~2020~~2023, ~~Chu~~Kho ~~Pao-Chi~~& Patel, ~~Chairman~~Certified ofPublic ~~the Board of Directors~~Accountants, ~~and~~ ~~Chief Executive Officer of the Company~~(“Kho”), resigned ~~his~~as ~~position~~the asindependent ~~CEO~~registered ~~and~~public ~~current~~accounting ~~secretary~~firm of ~~the Company, Kao Cheng-Hsiang, was appointed~~Vitaspring ~~CEO~~Biomedical ~~and~~Co. ~~retains~~Ltd. ~~his~~(the ~~position as Secretary~~“Company”).

~~The~~Kho ~~remaining~~& ~~officers~~Patel's ofreport on the ~~Company~~financial statements for the fiscal years ended January 31, ~~Lin~~2022 ~~Jer-Li~~and ~~Chief~~January ~~Technical~~31, ~~Officer of~~2021, the ~~Company~~last ~~and~~reports ~~Chen~~issued ~~Yen~~by ~~Xun~~Kho, ~~Technical~~contained ~~Vice-President~~no adverse opinion or disclaimer of ~~the~~opinion, ~~Company~~and were not qualified or modified as to uncertainty, ~~remain~~audit ~~the~~scope ~~same~~or accounting principle, other than an explanatory paragraph as to a going concern.

~~Signatures~~During the fiscal the years ended January 31, 2022 and January 31, 2021, and in the subsequent interim periods October 31, 2022, July 21, 2022 and April 30, 2022, through January 17, 2023, the date of the resignation of Kho & Patel, (a) there were no disagreements with Kho & Patel on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Kho & Patel, would have caused them to make reference to the subject matter of the disagreements in its reports on the financial statements for such year and (b) there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.

~~Pursuant~~We tohave ~~the~~provided ~~requirements~~a copy of the ~~Securities~~ ~~Exchange~~disclosures ~~Act~~contained ofherein ~~1934~~to Kho & Patel on January 27, ~~the~~2023, ~~Registrant~~and ~~has~~requested ~~duly~~Kho ~~caused~~& ~~this~~Patel ~~report~~to provide it with a letter addressed to bethe ~~signed~~U.S. onSecurities ~~its~~and ~~behalf~~Exchange byCommission stating whether or not Kho & Patel agrees with the ~~undersigned~~above ~~hereunto~~disclosures. ~~duly~~A ~~authorized~~copy of Kho & Patel’s response letter is attached hereto as Exhibit 16.1.

~~VITASPRING~~(b) ~~BIOMEDICAL~~New ~~CO.~~Independent ~~LTD.~~Registered ~~August~~Public ~~11, 2021 By: /s/ Kao Cheng-Hsiang Kao Cheng-Hsiang Chief Executive Officer~~Accounting Firm

On January 24, 2023, our board of directors approved the engagement of TAAD LLP (“TAAD”), as the Company’s new independent registered public accounting firm.

During the Company’s most recent fiscal year end and any subsequent interim period preceding the engagement of TAAD, neither the Company nor anyone acting on our behalf, has consulted with TAAD regarding either: (i) the application of accounting principles to a specified transaction, either contemplated or proposed, (ii) the type of audit opinion that might be rendered on the Company’s financial statements, or (iii) any matter that was either the subject of a disagreement between the Company and TAAD as described in Item 304(a)(1)(iv) of Regulation S-K or a reportable event as described in Item 304(a)(1)(v) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

16.1 Letter from Kho & Patel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Vitaspring Biomedical Co. Ltd.

Date: January 27, 2023	By:	/s/ Kao, Cheng-Hsiang
		Name: Kao, Cheng-Hsiang
		Title: Chief Executive Officer

Filing Compare · VITASPRING BIOMEDICAL CO. LTD.